By Ben Glickman


Shares of Invivyd eased in after-hours trading Friday, pulling back from regular-session gains on news of emergency approval for its monoclonal antibody treatment.

Shares were down 2.8% to $4.24 in after-hours trading, following a 41% rise at Friday's close. The stock has risen 12% in the last three months.

Invivyd said Friday that the Food and Drug Administration had given emergency-use permission to Pemgarda for preventing Covid-19 in immunocompromised adolescents and adults.

The treatment is administered as an intravenous infusion and is indicated for people 12 and older weighing at least 40 kilograms, or about 88 pounds.

Chief Executive David Hering said the company expected to have product available in the U.S. imminently.


Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

03-22-24 1846ET